Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C.

[1]  E. Sagnelli,et al.  Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  E. Sagnelli,et al.  Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C , 2013, Journal of viral hepatitis.

[3]  E. Sagnelli,et al.  Outcomes , and Response to Therapy Among Patients with Acute Exacerbation of Chronic Hepatitis C , 2013 .

[4]  F. Locatelli,et al.  Cannabinoid Receptor Type 2 Functional Variant Influences Liver Damage in Children with Non-Alcoholic Fatty Liver Disease , 2012, PloS one.

[5]  A. Fasano,et al.  The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. , 2012, Pharmacological research.

[6]  S. Perrotta,et al.  CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura , 2011, Haematologica.

[7]  A. Mallat,et al.  Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice , 2011, Hepatology.

[8]  L. Perrone,et al.  Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: An alternative way to highlight the CB2 hepatoprotective properties , 2011, Hepatology.

[9]  A. de Gottardi,et al.  Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[10]  D. van der Poorten,et al.  Hepatitis C Virus Induces the Cannabinoid Receptor 1 , 2010, PloS one.

[11]  T. Tordjmann,et al.  Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration , 2010, Hepatology.

[12]  Hong Liu,et al.  Anandamide induces cell death through lipid rafts in hepatic stellate cells , 2010, Journal of gastroenterology and hepatology.

[13]  W. M. Williams,et al.  Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor , 2010, Pharmacogenetics and genomics.

[14]  L. Adinolfi,et al.  Long‐term outcome of hepatitis B and hepatitis C virus co‐infection and single HBV infection acquired in youth , 2009, Journal of medical virology.

[15]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[16]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[17]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[18]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[19]  Andreas Zimmer,et al.  Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis , 2009, PloS one.

[20]  D. Osei-Hyiaman,et al.  Endocannabinoids and the Control of Energy Homeostasis* , 2008, Journal of Biological Chemistry.

[21]  G. Uhl,et al.  Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression , 2008, Annals of the New York Academy of Sciences.

[22]  M. Ostrowski,et al.  Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. , 2008, Gastroenterology.

[23]  A. Mallat,et al.  Environmental factors as disease accelerators during chronic hepatitis C. , 2008, Journal of hepatology.

[24]  P. Bacchetti,et al.  Influence of cannabis use on severity of hepatitis C disease. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  R. Schwabe,et al.  The endocannabinoid 2‐arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[27]  E. Blanchard,et al.  Subcellular Localization of Hepatitis C Virus Structural Proteins in a Cell Culture System That Efficiently Replicates the Virus , 2006, Journal of Virology.

[28]  E. Sagnelli,et al.  Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[29]  S. Bird,et al.  Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  A. Gerber,et al.  Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders , 2005, Journal of leukocyte biology.

[31]  F. Roudot-thoraval,et al.  Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C , 2005, Hepatology.

[32]  R. Schwabe,et al.  Anandamide induces necrosis in primary hepatic stellate cells , 2005, Hepatology.

[33]  K. Reddy,et al.  Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population , 2004, Hepatology.

[34]  M. Lai,et al.  Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. , 2004, Virology.

[35]  J. Satsangi,et al.  Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP‐2, with outcome of HCV infection , 2003, Hepatology.

[36]  A. Bosserhoff,et al.  A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. , 2003, Gastroenterology.

[37]  R. Gish,et al.  Rate of natural disease progression in patients with chronic hepatitis C. , 2003, Journal of hepatology.

[38]  C. Katlama,et al.  Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy , 2001, Hepatology.

[39]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[40]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[41]  R. Smart,et al.  Drug use and drinking among students in 36 countries. , 2000, Addictive behaviors.

[42]  G. Ostapowicz,et al.  Role of alcohol in the progression of liver disease caused by hepatitis C virus infection , 1998, Hepatology.

[43]  E. Tanaka,et al.  The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses , 1996, Hepatology.

[44]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .